Association study of CYP17 and HSD11B1 in polycystic ovary syndrome utilizing comprehensive gene coverage

Molecular Human Reproduction

Volumn 18, Issue 6, 2012, Pages 320-324

  Chua, Angela K ^a   Azziz, Ricardo ^a,b   Goodarzi, Mark O ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

CYP17; Haplotype; HSD11B1; Polycystic ovary syndrome; Single nucleotide polymorphism

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CYTOCHROME P450C17;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADOLESCENT; ADULT; ALABAMA; ALLELES; COHORT STUDIES; EXONS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; INTRONS; LINKAGE DISEQUILIBRIUM; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; QUANTITATIVE TRAIT LOCI; STEROID 17-ALPHA-HYDROXYLASE; YOUNG ADULT;

EID: 84861737570     PISSN: 13609947     EISSN: 14602407     Source Type: Journal    
DOI: 10.1093/molehr/gas002     Document Type: Article

References (29)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-2749.
2. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
3. Boots LR, Potter S, Potter D, Azziz R. Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. Fertil Steril 1998;69:286-292.
4. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994;3:1873-1876.
5. Diamanti-Kandarakis E, Bartzis MI, Zapanti ED, Spina GG, Filandra FA, Tsianateli TC, Bergiele AT, Kouli CR. Polymorphism T-.C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 1999;71:431-435.
6. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I et al. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 2003;34:434-439.
7. Draper N, Powell BL, Franks S, Conway GS, Stewart PM, McCarthy MI. Variants implicated in cortisone reductase deficiency do not contribute to susceptibility to common forms of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006;65:64-70.
8. Echiburu B, Perez-Bravo F, Maliqueo M, Sanchez F, Crisosto N, Sir-Petermann T. Polymorphism T -. C (-34 base pairs) of gene CYP17 promoter in women with polycystic ovary syndrome is associated with increased body weight and insulin resistance: a preliminary study. Metabolism 2008;57:1765-1771.
9. Gambineri A, Vicennati V, Genghini S, Tomassoni F, Pagotto U, Pasquali R, Walker BR. Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:2295-2302.
10. Gambineri A, Tomassoni F, Munarini A, Stimson R, Mioni R, Pagotto U, Chapman K, Andrew R, Mantovani V, Pasquali R et al. Combination of polymorphisms in HSD11B1 associate with in vivo 11b-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. Eur J Endocrinol 2011;165:283-292.
11. Gharani N, Waterworth DM, Williamson R. Franks S. 5' polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. J Clin Endocrinol Metab 1996;81:4174.
12. Gilep AA, Sushko TA, Usanov SA. At the crossroads of steroid hormone biosynthesis: the role, substrate specificity and evolutionary development of CYP17. Biochim Biophys Acta 2011;1814:200-209.
13. Goodarzi MO. Looking for polycystic ovary syndrome genes: rational and best strategy. Semin Reprod Med 2008;26:5-13.
14. Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab 2006; 20:193-205.
15. Goodarzi MO, Guo X, Taylor KD, Quinones MJ, Samayoa C, Yang H, Saad MF, Palotie A, Krauss RM, Hsueh WA et al. Determination and use of haplotypes: ethnic comparison and association of the lipoprotein lipase gene and coronary artery disease in Mexican-Americans. Genet Med 2003;5:322-327.
16. Goodarzi MO, Shah NA, Antoine HJ, Pall M, Guo X, Azziz R. Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J Clin Endocrinol Metab 2006;91:4085-4091.
17. Kahsar-Miller M, Boots LR, Bartolucci A, Azziz R. Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. Fertil Steril 2004;82:973-975.
18. Legro RS, Driscoll D, Strauss JF, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998;95:14956-4960.
19. Liovic M, Prezelj J, Kocijancic A, Majdic G, Komel R. CYP17 gene analysis in hyperandrogenised women with and without exaggerated 17-hydroxyprogesterone response to ovarian stimulation. J Endocrinol Invest 1997;20:189-193.
20. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 1999;14:143-149.
21. Marszalek B, Lacinski M, Babych N, Capla E, Biernacka-Lukanty J, Warenik-Szymankiewicz A, Trzeciak WH. Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5'-UTR in patients with polycystic ovarian syndrome. Gynecol Endocrinol 2001;15:123-128.
22. Park JM, Lee EJ, Ramakrishna S, Cha DH, Baek KH. Association study for single nucleotide polymorphisms in the CYP17A1 gene and polycystic ovary syndrome. Int J Mol Med 2008;22:249-254.
23. Perez MS, Cerrone GE, Benencia H, Marquez N, De Piano E, Frechtel GD. Polymorphism in CYP11alpha and CYP17 genes and the etiology of hyperandrogenism in patients with polycystic ovary syndrome. Medicina (B Aires) 2008;68:129-134.
24. Pusalkar M, Meherji P, Gokral J, Chinnaraj S, Maitra A. CYP11A1 and CYP17 promoter polymorphisms associate with hyperandrogenemia in polycystic ovary syndrome. Fertil Steril 2009;92:653-659.
25. San Millan JL, Botella-Carretero JI, Alvarez-Blasco F, Luque-Ramirez M, Sancho J, Moghetti P, Escobar-Morreale HF. A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4157-4162.
26. Techatraisak K, Conway GS, Rumsby G. Frequency of a polymorphism in the regulatory region of the 17 alpha-hydroxylase-17,20-lyase (CYP17) gene in hyperandrogenic states. Clin Endocrinol (Oxf) 1997;46:131-134.
27. The International HapMap Consortium. The International HapMap Project. Nature 2003;426:789-796.
28. Unsal T, Konac E, Yesilkaya E, Yilmaz A, Bideci A, Ilke Onen H, Cinaz P, Menevse A. Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. J Assist Reprod Genet 2009;26:205-216.
29. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR (eds). Polycystic Ovary Syndrome. Cambridge: Blackwell Scientific Publications, 1992, 377-384.